Another positive EBITDA of $0.5M, an impressive $7.5M turnaround.
We’re firmly on the path to profitability, and there’s no way we’ll stay under 20c for long.
Momentum is building, and we’re accelerating toward sustained profitability.
Key Highlights
- Robust 1HY25 Group Performance: Executing successfully against Bubs’ strategic plan
- Statutory NPAT of $3.6M, an $11.2M improvement YoY.
- EBITDA of $0.5M, a $7.5M uplift from 1HY24
- Cash flow transformation: Operating cash outflow reduced to just $0.5M (vs. $12.2M in 1HY24), with a strong liquidity position—$17.2M in cash plus $5.0M in undrawn debt
- Gross profit margins hitting 50%, well ahead of plan.
- Revenue up 23% on pcp to $48M, all regions showing strong growth over pcp.
- Forums
- ASX - By Stock
- Ann: Bubs Australia - Half Year Results Presentation
BUB
bubs australia limited
Add to My Watchlist
5.56%
!
17.0¢

Another positive EBITDA of $0.5M, an impressive $7.5M...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
17.0¢ |
Change
-0.010(5.56%) |
Mkt cap ! $151.8M |
Open | High | Low | Value | Volume |
18.0¢ | 18.0¢ | 17.0¢ | $170.5K | 979.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
24 | 716290 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.5¢ | 97636 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 645650 | 0.170 |
7 | 369412 | 0.165 |
14 | 400986 | 0.160 |
23 | 1360110 | 0.155 |
23 | 1338487 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.175 | 47636 | 5 |
0.180 | 912370 | 19 |
0.185 | 226700 | 6 |
0.190 | 481314 | 13 |
0.195 | 322491 | 6 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
BUB (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online